NCT00415311View on ClinicalTrials.gov

A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions
Liver Transplantation
Interventions
DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

DRUG

Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Trial Locations (4)

10029

Mount Sinai School of Medicine, New York

94143

University of California San Francisco, San Francisco

372321

Vanderbilt University, Nashville

68198-7400

Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY